Amylyx Pharmaceuticals Quarterly Income Statement
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
28.14+0.94 (+3.46%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amylyx Pharmaceuticals revenue and earnings
Amylyx Pharmaceuticals reported a net loss of $43.4 million, compared with a loss of $41.4 million a year earlier. Diluted earnings per share came in at -$0.39.
Summary generated from market data by MetaCap's automated system. Methodology
Amylyx Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | -665.00K | 416.00K | -1.02M | 88.64M | 108.45M | 102.69M |
| Revenue growth (YoY) | — | — | — | -100.00% | — | -100.00% | -100.61% | -99.59% | -101.04% | +24.10% | +395.54% | +29666.09% |
| Cost of Revenue | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 8.00K | 5.95M | 9.36M | 5.22M |
| Gross Profit | — | — | 0 | 0 | 0 | 0 | -665.00K | 416.00K | -1.03M | 82.70M | 99.09M | 97.47M |
| Operating Expenses | — | — | 36.60M | 36.03M | 42.86M | 37.80M | 39.99M | 76.08M | 75.25M | 204.83M | 97.16M | 78.75M |
| Research & Development | 23.77M | 27.61M | 21.21M | 19.86M | 27.22M | 22.12M | 22.89M | 21.24M | 23.35M | 36.61M | 44.91M | 30.04M |
| Selling, General & Admin | 21.93M | 16.17M | 15.39M | 16.17M | 15.64M | 15.68M | 17.10M | 17.83M | 21.65M | 57.76M | 52.24M | 48.72M |
| Operating Income | -45.69M | -43.78M | -36.60M | -36.03M | -42.86M | -37.80M | -40.65M | -75.66M | -76.29M | -122.13M | 1.93M | 18.72M |
| Other Income (Expense) | 2.27M | 2.50M | 3.65M | 1.64M | 1.41M | 1.90M | 2.47M | 2.96M | 3.59M | 3.58M | 4.54M | 3.69M |
| Pretax Income | — | — | -32.95M | -34.39M | -41.44M | -35.91M | -38.18M | -72.70M | -72.70M | -118.55M | 6.48M | 22.41M |
| Income Tax | — | — | 46.00K | 0 | 0 | 0 | -635.00K | 0 | 0 | 242.00K | 1.75M | 1.52M |
| Net Income | -43.42M | -41.28M | -33.00M | -34.39M | -41.44M | -35.91M | -37.55M | -72.70M | -72.70M | -118.79M | 4.73M | 20.89M |
| Net Income growth (YoY) | — | — | — | — | — | — | -893.62% | -447.98% | -429.35% | -7652.00% | — | — |
| EPS (Basic) | -0.39 | -0.37 | -0.28 | -0.37 | -0.46 | -0.42 | -0.54 | -1.07 | -1.07 | -1.75 | 0.07 | 0.31 |
| EPS (Diluted) | -0.39 | -0.37 | -0.28 | -0.37 | -0.46 | -0.42 | -0.54 | -1.07 | -1.07 | -1.75 | 0.07 | 0.30 |
| Shares Outstanding (Basic) | 111.20M | 110.56M | — | 93.33M | 89.14M | 85.70M | — | 68.09M | 68.02M | 67.85M | — | 67.41M |
| Shares Outstanding (Diluted) | 111.20M | 110.56M | — | 93.33M | 89.14M | 85.70M | — | 68.09M | 68.02M | 67.85M | — | 69.75M |
| EBITDA | -45.65M | -43.68M | -36.50M | -35.91M | -42.72M | -37.65M | -40.49M | -75.44M | -76.08M | -121.81M | 2.23M | 19.02M |
| Gross Margin | — | — | — | — | — | — | 100.00% | 100.00% | 100.78% | 93.29% | 91.37% | 94.92% |
| Operating Margin | — | — | — | — | — | — | 6113.38% | -18187.74% | 7457.09% | -137.78% | 1.78% | 18.23% |
| Net Margin | — | — | — | — | — | — | 5646.02% | -17476.92% | 7106.55% | -134.01% | 4.36% | 20.35% |
This table shows 12 quarterly periods of Amylyx Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AMLX's reporting calendar. What is a income statement?